Book a Meeting

Non-fucosylated Anti-Human CD40 (Lucatumumab) Therapeutic Antibody (CAT#: BioBet-149ZP) Datasheet

Target
CD40
Isotype
IgG1, κ
Description
ADCC-enhanced Lucatumumab is a non-fucosylated anti-CD40 therapeutic biobetter antibody.
Indication
Lymphoma, B cell
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD40 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD40
Full Name
CD40 Molecule
Background
CD40 (CD40 Molecule) is a Protein Coding gene.
Diseases associated with CD40 include Immunodeficiency With Hyper-Igm, Type 3 and Cd40 Ligand Deficiency.
Among its related pathways are NLR Proteins and Cytokine Signaling in Immune system.
Gene Ontology (GO) annotations related to this gene include enzyme binding and receptor activity.
An important paralog of this gene is TNFRSF11A.
Alternative Names
Tumor necrosis factor receptor superfamily member 5; TNFRSF5; p50
Gene ID
958
UniProt ID
P25942
Cellular Localization
Plasma membrane, Extracellular region or secreted
Involvement in Disease
Diseases associated with CD40 include Immunodeficiency With Hyper-Igm, Type 3 and Immunodeficiency With Hyper-Igm, Type 1.
Related Pathways
Its related pathways are Transcriptional misregulation in cancer and NF-KappaB Family Pathway.
Function
TNFSF5/CD40LG receptor (PubMed: 31331973). ERK is activated by TRAF6- and map3k8-mediated signals in macrophages and B cells, leading to the induction of immunoglobulin secretion (by similarity).
Field of research
Cell Biology and Cellular Response antibody; Developmental Biology antibody; Immune System antibody; Pro-B Cell Marker antibody; Pre-B Cell Marker antibody
Post-translational modifications
1.Glycosylation at Asn153 and Asn180 2.Glycosylation at Asn153 and Asn180 3.Glycosylation at Asn153 and Asn180
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, κ
Antibody Clone
Lucatumumab
Host
Human
Species Reactivity
Human
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human monoclonal antibody expressed in CHO binding to human CD40. Lucatumumab is a human monoclonal antibody being investigated for the treatment of various types of cancer like multiple myeloma, non-Hodgkin's or Hodgkin's lymphoma.
Indication
Lymphoma, B cell

Lymphoma, B cell

Related Products

BetterBet™ Anti-CD40 On-Target Antibody (CAT#: AES-0622-ZP703)
BetterBet™ Anti-CD40 FcγRIIB Binding Enhanced Antibody (CAT#: AES-0622-ZP375)
Non-fucosylated Anti-Human CD40 (Teneliximab) Therapeutic Antibody (CAT#: BioBet-147ZP)
Non-fucosylated Anti-Human CD40 (Dacetuzumab) Therapeutic Antibody (CAT#: BioBet-146ZP)
Highly Galactosylated Anti-CD40 (Bleselumab) Antibody (CAT#: BioBet-GA-145ZP)
BetterBet™ Anti-CD40 Half-Life Extended Antibody (CAT#: AES-0622-ZP1031)
Highly Galactosylated Anti-CD40 (Teneliximab) Antibody (CAT#: BioBet-GA-147ZP)
BetterBet™ Anti-CD40 Recycling Antibody (CAT#: AES-0622-ZP47)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany